A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

I8B-MC-ITSW -

This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
Insulin Glargine, LY900014
Could I receive a Placebo?
No
Enrollment Goal
187
Trial Dates
Nov 4, 2020 - Feb 4, 2022
How long will I be in the trial?
The study will last about 19 weeks and may include up to 13 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have a diagnosis of type 2 diabetes for at least 1 year

  • Participants must have already been treated with long-acting and mealtime insulins required for study participation

  • Participants blood glucose levels must be within allowed limits for study participation

Participants Must Not:

  • Participants must not have had emergency treatment for very low blood glucose or very high blood glucose within the past 6 months

  • Participants must not be taking certain diabetes medications that are not allowed for study participation

  • Participants must not have major problems with their heart, kidney, liver, or have a blood disorder

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.